文献速递头颈与中枢神经肿瘤

替西罗莫司联合低剂量卡铂紫杉醇治疗复发/转移性头颈鳞癌的II期研究

A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
PubMed 文献 · Ann Oncol · 2017-01-01

单中心II期研究评估替西罗莫司25 mg联合卡铂AUC 1.5及紫杉醇80 mg/m²(21天周期第1、8天)治疗36例复发/转移性头颈鳞癌,客观缓解率41.7%(均为部分缓解),中位无进展生存5.9个月,中位总生存12.8个月,常见3/4级不良事件为血液学毒性。

要点

  • 36例可评估患者中15例(41.7%)达客观缓解,均为部分缓解。
  • 中位无进展生存5.9个月(95%CI 4.8-7.1),中位总生存12.8个月(95%CI 9.8-15.8)。
  • 4例PIK3CA突变患者中3例出现肿瘤退缩,PI3K/mTOR通路其他遗传改变者也见缓解。

核心结论

  • 替西罗莫司联合低剂量每周卡铂和紫杉醇在复发/转移性头颈鳞癌中似乎具有有意义的临床疗效。
  • 该方案相比其他评估过的复发/转移性头颈鳞癌治疗具有相对较高的缓解率,与PI3K/mTOR通路遗传改变的潜在关联应进一步探索。

研究设计与样本

  • 单中心II期研究,纳入36例复发和/或转移性头颈鳞癌患者。
  • 治疗方案为替西罗莫司25 mg、卡铂AUC 1.5、紫杉醇80 mg/m²,于21天周期第1天和第8天给药。
  • 主要终点为两个周期后的客观缓解率;次要终点包括安全性和耐受性及总生存。
  • 对21例患者治疗前活检样本进行外显子组突变分析的相关研究。

主要发现

  • 15例(41.7%)患者达客观缓解,均为部分缓解;19例(52.3%)最佳疗效为疾病稳定。
  • 2例被指定为「无缓解」的患者在两个周期治疗前退出研究,但仍纳入疗效和安全性分析。
  • 中位研究持续时间为5.3个月,中位无进展生存5.9个月(95%CI 4.8-7.1),中位总生存12.8个月(95%CI 9.8-15.8)。
  • 最常见的3级和4级不良事件为血液学毒性;3例(3.8%)患者在研究期间发生中性粒细胞减少性发热。
  • 4例PIK3CA突变患者中3例出现肿瘤退缩,PI3K/mTOR通路其他遗传改变的患者也观察到缓解。

临床怎么用

  • 该联合方案在复发/转移性头颈鳞癌中显示出相对较高的缓解率和可管理的安全性,可作为临床参考。
  • 治疗期间需关注血液学毒性,包括中性粒细胞减少性发热。
  • PI3K/mTOR通路遗传改变与缓解的潜在关联值得进一步探索。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Activating events along the PI3K/mTOR pathway are common in head and neck squamous cell carcinomas (HNSCC), and preclinical studies suggest additive or synergistic effects when combining mTORC1 inhibitors with carboplatin and paclitaxel chemotherapy. PATIENTS AND METHODS: In this single-institution phase II study, the combination of temsirolimus 25 mg, carboplatin AUC 1.5, and paclitaxel 80 mg/m2 administered on days 1 and 8 of a 21-day cycle was evaluated in 36 patients with recurrent and/or metastatic (R/M) HNSCC. The primary end point was objective response rate after two cycles of treatment. Secondary end points include the safety and tolerability profile and overall survival. Correlative studies with exome mutational analysis were performed in pre-treatment biopsy samples from 21 patients. RESULTS: Fifteen (41.7%) patients had an objective response, which were all partial responses, and 19 (52.3%) patients had stable disease as best response. The two patients who were designated as 'non-responders' were removed from study prior to two cycles of treatment, but are included in the efficacy and safety analyses. The median duration on study was 5.3 months and the median progression-free survival and overall survival were 5.9 months (95% confidence interval, 4.8-7.1) and 12.8 months (95% confidence interval, 9.8-15.8), respectively. The most common grade 3 and 4 adverse events were hematologic toxicities. Three (3.8%) patients developed neutropenic fever on study. Three of four patients with PIK3CA mutations experienced tumor regressions, and responses were also seen in patients with other genetic alterations in the PI3K/mTOR pathway. CONCLUSION: The combination of temsirolimus with low-dose weekly carboplatin and paclitaxel appears to have meaningful clinical efficacy in the treatment of R/M HNSCC. This regimen has a relatively high response rate compared to other treatments evaluated in R/M HNSCC, and potential associations with genetic alterations in the PI3K/mTOR pathway should be further explored.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Dunn LA, Fury MG, Xiao H, et al. A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Ann Oncol. 2017. PMID: 28961834. doi:10.1093/annonc/mdx346

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。